Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results